Aspire BioPharma is trading $7.78 (+10.20%) as stronger biotech-sector sentiment appears linked to broader M&A optimism, though company-specific causation remains unconfirmed.
- No identified company-specific announcement was reported on August 7, 2026.
- argenx formally commenced its $2.2 billion tender offer for Forte Biosciences at $77 per share on August 6.
- Biotech M&A optimism is supporting broader sector participation.